The FDA database lists a supplement, dated 16 September 2026, to abbreviated new drug application ANDA202862 for olanzapine, held by Macleods Pharmaceuticals. A supplement to a generic application usually covers manufacturing, labelling or packaging changes to a product that is already approved.
The record does not describe a new indication, a safety communication or a change in how olanzapine should be used. Macleods is an Indian manufacturer, but the record concerns the US product, and nothing here changes prescribing in India.
- No change to olanzapine prescribing follows from this record.
- Continue routine metabolic monitoring on olanzapine: weight, waist, glucose or HbA1c and lipids.
- Check the label if your supply changes manufacturer and a patient reports a difference.
Why it matters
Generic supplements appear often; knowing they rarely carry clinical news saves a reader time.
Don't overread it
A supplement to a generic application is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free